• H2020
• Societal Challenges
• Health

A German-American cancer molecular diagnostics company has announced it will receive a €2.77m Horizon 2020 grant to fund the clinical research to validate Epigenomics’s proprietary lung cancer biomarkers.

Epigenomics AG aims to develop a CE-marked product for the detection of lung cancer in blood plasma under the new in vitro diagnostic directive. The funding comes from the Industrial Leadership pillar of the EU R&I framework programme and the grant duration is expected to be 24 months.

Speaking about the positive results and upcoming project, Dr Uwe Staub, chief operating officer of Epigenomics, said: “We are proud, that our lung cancer grant application has received the favour of the Horizon 2020 programme. With our Epi proLung® test, we have already proven that new and innovative diagnostic tests can make a difference in the detection of lung cancer.

“With this new project, we will clinically validate a novel CE-marked diagnostic product that can detect lung cancer in blood plasma at an early stage and has a variety of possible future clinical applications in the diagnosis of lung cancer.”

Epigenomics is a molecular diagnostics company developing and commercialising innovative products for cancer.